Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 2
Submit an article Journal homepage
260
Views
38
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs for respiratory syncytial virus infection

Wieslawa Olszewska National Heart and Lung Institute, Centre for Respiratory Infection, Imperial College London, St Mary's Campus, Norfolk Place, Paddington, W2 1PG, London, UK +44 207 594 3853/4; +44 207 262 8913; [email protected]
&
Peter Openshaw National Heart and Lung Institute, Centre for Respiratory Infection, Imperial College London, St Mary's Campus, Norfolk Place, Paddington, W2 1PG, London, UK +44 207 594 3853/4; +44 207 262 8913; [email protected]
Pages 207-217 | Published online: 20 May 2009

Bibliography

  • Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006;368(9532):312-22
  • Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6
  • Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004;22(5):275-84
  • Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360(6):588-98
  • Wu P, Dupont WD, Griffin MR, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med 2008;178(11):1123-9
  • Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171(2):137-41
  • Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151(1):34-42
  • Falsey AR, Formica MA, Hennessey PA, et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(6):639-43
  • Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000;13(3):371-84
  • Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999;179(1):25-30
  • Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009;83(3):1492-500
  • Openshaw PJ, Tregoning JS. Immuneresponses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005;18(3):541-55
  • Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34
  • Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991;65:5425-34
  • Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987;84:5625-9
  • Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immun 2001;2(8):732-8
  • Cane PA, Thomas HM, Simpson AF, et al. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol 1996;48(3):253-61
  • Hendry RM, Burns JC, Walsh EE, et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 1988;157:640-7
  • Tuschl T, Zamore PD, Lehmann R, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13(24):3191-7
  • Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000;44(4):859-66
  • Hegele RG, Hayashi S, Bramley AM, Hogg JC. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs. Chest 1994;105:1848-54
  • Valarcher JF, Bourhy H, Lavenu A, et al. Persistent infection of B lymphocytes by bovine respiratory syncytial virus. Virology 2001;291(1):55-67
  • Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 2004;169(7):801-5
  • Wilkinson TM, Donaldson GC, Johnston SL, et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(8):871-6
  • Culley FJ, Pennycook AM, Tregoning JS, et al. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 2006;80(9):4521-7
  • Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006;12(8):905-7
  • Pitrez PM, Ponzi D, Machado DC, et al. Discrepancy between cytokine production from peripheral blood mononuclear cells and nasal secretions among infants with acute bronchiolitis. Ann Allergy Asthma Immunol 2004;92(6):659-62
  • Schauer U, Hoffjan S, Rothoeft T, et al. Severe respiratory syncytial virus infections and reduced interferon-gamma generation in vitro. Clin Exp Immunol 2004;138(1):102-9
  • Legg JP, Hussain IR, Warner JA, et al. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003;168(6):633-9
  • Dodd J, Riffault S, Kodituwakku JS, et al. Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease. J Immunol 2009;182(2):1174-81
  • Aoyagi M, Shimojo N, Sekine K, et al. Respiratory syncytial virus infection suppresses IFN-gamma production of gammadelta T cells. Clin Exp Immunol 2003;131(2):312-7
  • Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007;196(6):826-34
  • Pribul PK, Harker J, Wang B, et al. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 2008;82(9):4441-8
  • Groskreutz DJ, Monick MM, Powers LS, et al. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006;176(3):1733-40
  • Monick MM, Yarovinsky TO, Powers LS, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003;278(52):53035-44
  • Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004;189(11):2057-63
  • Gagro A, Tominac M, Krsulovic-Hresic V, et al. Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. Clin Exp Immunol 2004;135(2):267-72
  • Hacking D, Knight JC, Rockett K, et al. Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun 2004;5(4):274-82
  • Bont L, Heijnen CJ, Kavelaars A, et al. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis. Eur Respir J 1999;14(1):144-9
  • McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005;191(8):1225-32
  • Smyth RL, Mobbs KJ, O'Hea U, et al. Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. Pediatr Pulmonol 2002;33(5):339-46
  • McNamara PS, Flanagan BF, Baldwin LM, et al. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Lancet 2004;363(9414):1031-7
  • Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005;350(1):126-44
  • Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008;317:103-23
  • Fenton C, Scott LJ, Plosker GL. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 2004;6(3):177-97
  • Null D Jr, Pollara B, Dennehy PH, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24(11):1021-3
  • Simoes EA, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993;147:303-6
  • Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12(36):iii, ix-86
  • Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res 2006;71(2-3):379-90
  • Hoffmann SH, Wade MJ, Staffa JA, et al. Dominant lethal study of ribavirin in male rats. Mutat Res 1987;188(1):29-34
  • Hoffmann SH, Staffa JA, Smith RA, et al. Inhalation toxicity of ribavirin in suckling ferrets. J Appl Toxicol 1987;7(5):343-51
  • Krilov LR, Mandel FS, Barone SR, Fagin JC. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group. Pediatr Infect Dis J 1997;16(3):273-6
  • Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 2002;21(5):479-81
  • Marquardt ED. Cost of ribavirin therapy for respiratory syncytial virus infection. J Pediatr 1995;126(5 Pt 1):847
  • Crotty S, Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 2002;4(13):1301-7
  • Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002;80(2):86-95
  • Cianci C, Meanwell N, Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 2005;55(3):289-92
  • Cianci C, Langley DR, Dischino DD, et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA 2004;101(42):15046-51
  • Cianci C, Genovesi EV, Lamb L, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 2004;48(7):2448-54
  • Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004;48(2):413-22
  • Informa UK Ltd. Pharmaprojects -Pharmaceutical Research & Development Pipeline Intelligence. 2008
  • Razinkov V, Huntley C, Ellestad G, Krishnamurthy G. RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res 2002;55(1):189-200
  • Huntley CC, Weiss WJ, Gazumyan A, et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 2002;46(3):841-7
  • Weiss WJ, Murphy T, Lynch ME, et al. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med Primatol 2003;32(2):82-8
  • Douglas JL, Panis ML, Ho E, et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 2005;49(6):2460-6
  • Bonfanti JF, Doublet F, Fortin J, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. J Med Chem 2007;50(19):4572-84
  • Andries K, Moeremans M, Gevers T, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 2003;60(3):209-19
  • Wyde PR, Chetty SN, Timmerman P, et al. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res 2003;60(3):221-31
  • Bonfanti JF, Meyer C, Doublet F, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 2008;51(4):875-96
  • Kimura K, Mori S, Tomita K, et al. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res 2000;47(1):41-51
  • Douglas JL. In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev Anti Infect Ther 2004;2(4):625-39
  • Shigeta S, Mori S, Baba M, et al. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother 1992;36(2):435-9
  • Lai SH, Stein DA, Guerrero-Plata A, et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther 2008;16(6):1120-8
  • Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7(3):187-95
  • Stein D, Foster E, Huang SB, et al. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997;7(3):151-7
  • Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001;20(23):6877-88
  • DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77(3):225-31
  • Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002;169(9):5196-201
  • Xiang TX, Li Y, Jiang Z, et al. RNA interference-mediated silencing of the Hsp70 gene inhibits human gastric cancer cell growth and induces apoptosis in vitro and in vivo. Tumori 2008;94(4):539-50
  • Hamasaki K, Nakao K, Matsumoto K, et al. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003;543(1-3):51-4
  • Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11(1):50-5
  • Henderson EA, Alber DG, Baxter RC, et al. 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 2007;50(7):1685-92
  • Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007;51(9):3346-53
  • Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368(3):652-65
  • Mejias A, Chavez-Bueno S, Raynor MB, et al. Motavizumab, a neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by RSV in the mouse model. Virol J 2007;4:109
  • Madaan A. Motavizumab: Humanized anti-RSV monoclonal antibody, prevention of RSV infection. Drugs Future 2008;33(3):203-5
  • Available from: http://www.reuters.com/article/euIpoNews/idUSLS22855520081128, [Accessed 2 April 2009]
  • Available from: http://www.symphogen.com/web/guest/sym003, [Accessed 20 February 2009]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.